Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: A randomized clinical trial

JAMA Surgery

Volumn 150, Issue 4, 2015, Pages 352-361

  Risstad, Hilde ^a,b   Søvik, Torgeir T ^a   Engström, My ^c   Aasheim, Erlend T ^a   Fagerland, Morten W ^a   Olsén, Monika Fagevik ^c   Kristinsson, Jon A ^a   Le Roux, Carel W ^c,d   Bøhmer, Thomas ^a   Birkeland, Kåre I ^a   Mala, Tom ^a   Olbers, Torsten ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; OPEN STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WEIGHT REDUCTION; ANALYSIS; ANTHROPOMETRY; BLOOD; CLINICAL TRIAL; DUODENUM; GLUCOSE BLOOD LEVEL; LAPAROSCOPY; MIDDLE AGED; NORWAY; OBESITY, MORBID; PROCEDURES; SWEDEN; TREATMENT OUTCOME;

ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; BODY MASS INDEX; DUODENUM; FEMALE; GASTRIC BYPASS; HUMANS; LAPAROSCOPY; LIPIDS; MALE; MIDDLE AGED; NORWAY; OBESITY, MORBID; QUALITY OF LIFE; SWEDEN; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84928110868     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.3579     Document Type: Article

References (51)

1. Suter M, Calmes JM, Paroz A, Romy S, Giusti V. Results of Roux-en-Y gastric bypass in morbidly obese vs superobese patients: similar body weight loss, correction of comorbidities, and improvement of quality of life. Arch Surg. 2009;144(4):312-318.
2. Christou NV, Look D, Maclean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg. 2006;244(5):734-740.
3. Topart P, Becouarn G, Ritz P. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis. 2013;9(4):526-530.
4. Nelson DW, Blair KS, Martin MJ. Analysis of obesity-related outcomes and bariatric failure rates with the duodenal switch vs gastric bypass for morbid obesity. Arch Surg. 2012;147(9):847-854.
5. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648-651.
6. Livhits M, Mercado C, Yermilov I, et al. Preoperative predictors of weight loss following bariatric surgery: systematic review. Obes Surg. 2012;22(1):70-89.
7. MacLean LD, Rhode BM, Nohr CW. Late outcome of isolated gastric bypass. Ann Surg. 2000;231(4):524-528.
8. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427-436.
9. Dolan K, Hatzifotis M, Newbury L, Lowe N, Fielding G. A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch. Ann Surg. 2004;240(1):51-56.
10. Newbury L, Dolan K, Hatzifotis M, Low N, Fielding G. Calcium and vitamin D depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13(6):893-895.
11. Hatizifotis M, Dolan K, Newbury L, Fielding G. Symptomatic vitamin A deficiency following biliopancreatic diversion. Obes Surg. 2003;13(4):655-657.
12. Finks JF, Kole KL, Yenumula PR, et al; Michigan Bariatric Surgery Collaborative from the Center for Healthcare Outcomes and Policy. Predicting risk for serious complications with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg. 2011;254(4):633-640.
13. Aasheim ET, Søvik TT, Bakke EF. Night blindness after duodenal switch. Surg Obes Relat Dis. 2008;4(5):685-686.
14. Søvik TT, Taha O, Aasheim ET, et al. Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. Br J Surg. 2010;97(2):160-166.
15. Aasheim ET, Björkman S, Søvik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90(1):15-22.
16. Søvik TT, Aasheim ET, Taha O, et al. Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med. 2011;155(5):281-291.
17. Søvik TT, Karlsson J, Aasheim ET, et al. Gastrointestinal function and eating behavior after gastric bypass and duodenal switch. Surg Obes Relat Dis. 2013;9(5):641-647.
18. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133-2135.
19. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
20. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
21. Svedlund J, Sjödin I, Dotevall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-134.
22. Osterberg A, Graf W, Karlbom U, Påhlman L. Evaluation of a questionnaire in the assessment of patients with faecal incontinence and constipation. Scand J Gastroenterol. 1996;31(6):575-580.
23. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903-912.
24. Karlsson J, Taft C, Sjöström L, Torgerson JS, Sullivan M. Psychosocial functioning in the obese before and after weight reduction: construct validity and responsiveness of the Obesity-related Problems scale. Int J Obes Relat Metab Disord. 2003;27(5):617-630.
25. 2) compared with gastric bypass. Ann Surg. 2006;244(4):611-619.
26. Laurenius A, Taha O, Maleckas A, Lönroth H, Olbers T. Laparoscopic biliopancreatic diversion/duodenal switch or laparoscopic Roux-en-Y gastric bypass for super-obesity-weight loss versus side effects. Surg Obes Relat Dis. 2010;6(4):408-414.
27. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737.
28. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256.e5.
29. 2) compared with gastric bypass. J Gastrointest Surg. 2010;14(2):211-220.
30. Dorman RB, Rasmus NF, Al-Haddad BJ, et al. Benefits and complications of the duodenal switch/biliopancreatic diversion compared to the Roux-en-Y gastric bypass. Surgery. 2012;152(4):758-765.
31. Hedberg J, Sundström J, Sundbom M. Duodenal switch versus Roux-en-Y gastric bypass for morbid obesity: systematic review and meta-analysis of weight results, diabetes resolution and early complications in single-centre comparisons. Obes Rev. 2014;15(7):555-563.
32. Tirosh A, Shai I, Tekes-Manova D, et al; Israeli Diabetes Research Group. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353(14):1454-1462.
33. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008;121(6):519-524.
34. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695-704.
35. Kolotkin RL, Davidson LE, Crosby RD, Hunt SC, Adams TD. Six-year changes in health-related quality of life in gastric bypass patients versus obese comparison groups. Surg Obes Relat Dis. 2012;8(5):625-633.
36. Aasprang A, Andersen JR, Våge V, Kolotkin RL, Natvig GK. Five-year changes in health-related quality of life after biliopancreatic diversion with duodenal switch. Obes Surg. 2013;23(10):1662-1668.
37. Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8):1248-1261.
38. Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev. 2014;15(3):169-182.
39. Mason RJ. Duodenal switch for morbid obesity: is it safe? Adv Surg. 2013;47:153-176.
40. Anthone GJ, Lord RV, De Meester TR, Crookes PF. The duodenal switch operation for the treatment of morbid obesity. Ann Surg. 2003;238(4):618-627.
41. Hamoui N, Chock B, Anthone GJ, Crookes PF. Revision of the duodenal switch: indications, technique, and outcomes. J AmColl Surg. 2007;204(4):603-608.
42. Marceau P, Biron S, Hould FS, et al. Duodenal switch: long-term results. Obes Surg. 2007;17(11):1421-1430.
43. Hess DS, Hess DW, Oakley RS. The biliopancreatic diversion with the duodenal switch: results beyond 10 years. Obes Surg. 2005;15(3):408-416.
44. Magee CJ, Barry J, Brocklehurst J, Javed S, Macadam R, Kerrigan DD. Outcome of laparoscopic duodenal switch for morbid obesity. Br J Surg. 2011;98(1):79-84.
45. Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8(1):48-55.
46. Topart P, Becouarn G, Sallé A, Ritz P. Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis. 2014;10(5):936-941.
47. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889-891.
48. De Maria EJ, Pate V, Warthen M, Winegar DA. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2010;6(4):347-355.
49. Iannelli A, Schneck AS, Dahman M, Negri C, Gugenheim J. Two-step laparoscopic duodenal switch for superobesity: a feasibility study. Surg Endosc. 2009;23(10):2385-2389.
50. Iannelli A, Schneck AS, Topart P, Carles M, Hébuterne X, Gugenheim J. Laparoscopic sleeve gastrectomy followed by duodenal switch in selected patients versus single-stage duodenal switch for superobesity: case-control study. Surg Obes Relat Dis. 2013;9(4):531-538.
51. Dapri G, Cadière GB, Himpens J. Superobese and super-superobese patients: 2-step laparoscopic duodenal switch. Surg Obes Relat Dis. 2011;7(6):703-708.